[go: up one dir, main page]

NO20072325L - Combination therapy including telmisartan and hydrochlorothiazide - Google Patents

Combination therapy including telmisartan and hydrochlorothiazide

Info

Publication number
NO20072325L
NO20072325L NO20072325A NO20072325A NO20072325L NO 20072325 L NO20072325 L NO 20072325L NO 20072325 A NO20072325 A NO 20072325A NO 20072325 A NO20072325 A NO 20072325A NO 20072325 L NO20072325 L NO 20072325L
Authority
NO
Norway
Prior art keywords
hydrochlorothiazide
telmisartan
combination therapy
therapy including
approx
Prior art date
Application number
NO20072325A
Other languages
Norwegian (no)
Inventor
Axel Riedel
Helmut E Schumacher
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072325(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20072325L publication Critical patent/NO20072325L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et farmasøytisk preparat omfattende ca. 80 mg telmisartan og ca. 25 mg hydroklortiazid eller ca. 160 mg telmisartan og ca. 50 mg hydroklortiazid for behandling av hypertensjon hos pasienter med en utilstrekkelig blodtrykkreduksjon etter behandling enten med en angiotensin II-reseptorantagonist eller et farmasøytisk preparat av en angiotensin II-reseptorantagonist og en lav dose av hydroklortiazid.A pharmaceutical composition comprising ca. 80 mg telmisartan and approx. 25 mg hydrochlorothiazide or approx. 160 mg telmisartan and approx. 50 mg hydrochlorothiazide for the treatment of hypertension in patients with inadequate blood pressure reduction after treatment with either an angiotensin II receptor antagonist or a pharmaceutical preparation of an angiotensin II receptor antagonist and a low dose of hydrochlorothiazide.

NO20072325A 2004-12-17 2007-05-04 Combination therapy including telmisartan and hydrochlorothiazide NO20072325L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (en) 2004-12-17 2005-12-09 Combination therapy comprising telmisartan and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
NO20072325L true NO20072325L (en) 2007-07-06

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072325A NO20072325L (en) 2004-12-17 2007-05-04 Combination therapy including telmisartan and hydrochlorothiazide

Country Status (15)

Country Link
EP (1) EP1827424A1 (en)
JP (1) JP2008524136A (en)
KR (1) KR20070097511A (en)
CN (1) CN101080225A (en)
AR (1) AR052052A1 (en)
AU (1) AU2005315855A1 (en)
BR (1) BRPI0519656A2 (en)
CA (1) CA2589493A1 (en)
EA (1) EA200701159A1 (en)
IL (1) IL183944A0 (en)
NO (1) NO20072325L (en)
PE (1) PE20060768A1 (en)
TW (1) TW200637546A (en)
UY (1) UY29274A1 (en)
WO (1) WO2006063737A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
DK2180882T3 (en) * 2007-10-19 2013-05-27 Otsuka Pharma Co Ltd Matrix-type pharmaceutical solid composition
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2009115301A1 (en) 2008-03-19 2009-09-24 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
AR072883A1 (en) 2008-07-31 2010-09-29 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION SOLID WITH THE COMPOUND (5-METHYL-2-OXO-1,3-DIOXOL-4-IL) METHYL2-ETOXI-1 - {[2 '- (5-OXO-4,5-DIHIDRO-1,2 , 4-OXADIAZOL-3-IL) BIFENIL-4-IL] METHYL} -1H-BENCIMIDAZOL-7-CARBOXYLATE AND A DIURÉTICO FOR THE PROPHYLAXIS OR TREATMENT OF DISEASES OF THE CIRCULATORY DEVICE.
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
HRP20130557T1 (en) 2009-06-19 2013-07-31 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
EP3025711B1 (en) * 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
CN106562973A (en) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 Anti-hypertension medicine compound preparation
CN107501192A (en) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 The eutectic of Telmisartan and Hydrochioro
CN108653227A (en) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 A kind of Telmisartan hydrochlorothiazide tablets and preparation method thereof
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (en) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated, divisible tablet
SI1467712T2 (en) * 2002-01-16 2011-11-30 Boehringer Ingelheim Pharma A process for the preparation of a two-layer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide

Also Published As

Publication number Publication date
BRPI0519656A2 (en) 2009-03-03
JP2008524136A (en) 2008-07-10
CA2589493A1 (en) 2006-06-22
IL183944A0 (en) 2007-10-31
EP1827424A1 (en) 2007-09-05
CN101080225A (en) 2007-11-28
KR20070097511A (en) 2007-10-04
AR052052A1 (en) 2007-02-28
WO2006063737A1 (en) 2006-06-22
EA200701159A1 (en) 2007-12-28
UY29274A1 (en) 2006-07-31
TW200637546A (en) 2006-11-01
AU2005315855A1 (en) 2006-06-22
PE20060768A1 (en) 2006-09-29

Similar Documents

Publication Publication Date Title
NO20072325L (en) Combination therapy including telmisartan and hydrochlorothiazide
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
JP6337170B2 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
EP2248519A3 (en) Non-mucoadhesive film dosage forms
CL2008003595A1 (en) Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system.
EA200800161A1 (en) NEW PHARMACEUTICAL COMPOSITIONS WITH MODIFIED DELIVERY AND METHOD OF OBTAINING SUCH COMPOSITIONS
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
NO20072931L (en) Improved dosing regimen of temozolomide for the treatment of cancer based on the patient's MGMT level
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
AR034517A1 (en) PHARMACEUTICAL FORMULATION
WO2007098387A3 (en) Antihypertensive therapy
RU2010107843A (en) BUPROPION HYDROBROMIDE AND ITS THERAPEUTIC APPLICATIONS
WO2010103365A3 (en) Sustained release composition of therapeutic agent
WO2010045417A3 (en) Combination therapies for the treatment of obesity
EA200600817A1 (en) ANTAGONISTS B1 BRADIKININ RECEPTOR (OPTIONS), PHARMACEUTICAL COMPOSITION, MEDICINAL MEDICINE, METHOD OF TREATMENT OF DISEASES (OPTIONS)
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
JP7109092B2 (en) Pharmaceutical patch for the treatment of neuropathic pain containing lidocaine and diclofenac
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
WO2004096118A3 (en) Composition for improving cognition and memory
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
JP7109093B2 (en) Dosing Regimens for Pharmaceutical Patches Containing Lidocaine and Diclofenac
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION
SE9902597D0 (en) New use
PT1408977E (en) COMBINATION THERAPY FOR CARDIAC FAILURE TREATMENT
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application